Mutations activating the function of ras proto-oncogenes are often observed in human tumors. Their oncogenic potential is mainly due to permanent stimulation of cellular proliferation and dramatic changes in morphogenic reactions of the cell. To learn more on the role of ras activation in cancerogenesis we studied its eects on chromosome stability and cell cycle checkpoints. Since the ability of ras oncogenes to cause cell transformation may be dependent on activity of the p53 tumorsuppressor the cells with dierent p53 state were analysed. Ectopic expression of N-ras asp12 caused in p53-de®cient MDAH041 cell line an augmentation in the number of chromosome breaks in mitogenic cells, signi®cant increase in the frequency of metaphases showing chromosome endoreduplication and accumulation of polyploid cells. Similar eects were induced by dierent exogenous ras genes (N-ras asp12 , H-ras leu12 , N-ras proto-oncogene) in Rat1 and Rat2 cells which have a defect in p53-upstream pathways. In contrast, in REF52 and human LIM1215 cells showing ras-induced p53 upregulation, ras expression caused only slight increase in the number of chromosome breaks and did not enhance the frequency of endoreduplication and polyploidy. Inactivation in these cells of p53 function by transduction of dominant-negative C-terminal p53 fragment (genetic suppressor element #22, GSE22) or mutant p53s signi®cantly increased the frequency of both spontaneous and ras-induced karyotypic changes. In concordance with these observations we have found that expression of ras oncogene caused in p53-defective cells further mitigation of ethyl-metansulphonate-induced G1 and G2 cell cycle arrest, but did not abrogate G1 and G2 cell cycle checkpoints in cells with normal p53 function. These data indicate that along with stimulation of cell proliferation and morphological transformation ras activation can contribute to cancerogenesis by increasing genetic instability.
Introduction
The members of ras family of proto-oncogenes including H-, K-, and N-ras, encode small GTPbinding proteins that transduce mitogenic signals from activated tyrosine-kinase receptors (reviewed in Barbacid, 1987; Marshall, 1996) . Ampli®cation of ras protooncogenes and mutations that constitutively activate Ras proteins are frequently observed in tumor cells. In fact, about 30% of all human tumors and up to 95% of human pancreatic cancers contain K-ras mutations (Barbacid, 1990; Rodenhuis, 1992) . Permanent activation of ras function via transduction of mutated ras oncogenes can cause oncogenic transformation of immortal cell lines, but fails to transform primary embryonic cells. In the latter case as well as in some established cell lines overexpression of activated ras causes cell cycle arrest in G1 or G2 phases (Franza et al., 1986; Hirakawa and Ruley, 1988; Hicks et al., 1991) which is probably due to accumulation of p53 tumor-suppressor and p16
ink4a
, an inhibitor of CDK4 Serrano et al., 1997) . Additional expression of cooperating oncogenes and mutant p53 in particular, releases ras-induced cell cycle growth arrest (Hicks et al., 1991; Serrano et al., 1997) and triggers formation of proliferating cells with typical transformed phenotype (Eliyahu et al., 1984; Jenkins et al., 1984; Parada et al., 1984; Hinds et al., 1990) .
Carcinogenesis is a multistep process in which accumulation of additional genomic alterations drives tumor progression. So genetic instability seems to be the basic feature of neoplastic cell essential for tumor development (Hartwell and Kastan, 1994; Kinzler and Vogelstein, 1997) . It is well established that dysfunction of p53 tumor-suppressor, the most common molecular alteration in dierent human tumors (Hollstein et al., 1994; Levine et al., 1995) , can lead to inactivation of cell cycle checkpoints and, as a result, to genetic instability. In fact, de®ciency in p53 leads to dramatic accumulation of aneuploid and polyploid cells (Harvey et al., 1993; Tsukada et al., 1993; Carder et al., 1993; Cross et al., 1995) , increases the yield of cell clones with cad gene ampli®cation (Livingstone et al., 1992; Yin et al., 1992) and enhances the frequency of chromsome breaks in dividing cells (Agapova et al., 1996) . The role of ras expression in induction of genetic instability is not so evident. It was reported that in mouse 3T3 cells activation of ras can increase frequency of chromosome breaks and heteroploidy (Denko et al., 1994) , however the dependence of rasinduced eects on the activity of p53 pathways remained unclear. In this study we analysed the effects of ras expression on karyotype stability and activity of cell cycle checkpoints in cells that dier in functional state of p53. The results indicate that ras activation is really able to increase frequency of various genomic alterations. However the pattern and quantity of rasinduced changes dier in cells with various abnormal-ities in pathways regulating p53 activity. These data allow to gain an additional insight to the role of ras oncogenes in cancerogenesis.
Results

Ras-induced karyotypic changes in cells with dierent p53 state
To analyse the eects of ras on karyotype stability we used cell lines diering in p53 function and generated on their basis sublines with conditional or constitutive expression of exogenous ras. In particular, we developed MDAH041, REF52 and Rat1 cell strains expressing N-ras asp12 under the control of tetracyclinerepressible promoter. Withdrawal of tetracycline caused in these cells morphological changes typical for ras-transformation (Figure 1 ).
First we studied eects of ras expression on chromosome stability in p53-de®cient human MDAH041/tet-ras cells. Control cultures of these cells maintained in the presence of tetracycline are characterized by very unstable karyotype similar to that described for other p53-negative cells (Harvey et al., 1993; Tsukuda et al., 1993; Cross et al., 1995; Agapova et al., 1996; Fukasawa et al., 1996) . The number of chromosomes in these cells varied from 60 ± 180 with no clear modal class. The chromosome breaks were found in more than half of cells with 2.5 breaks per metaphase, on average. Expression of N-ras asp12 oncogene induced by tetracycline withdrawal was accompanied by further increase in the number of chromosome breaks (Table 1) . However, the most prominent karyotypic eect of ras expression in MDAH041 cells was the induction of chromosome endoreduplication. In ras-transformed cultures 1 ± 2% of cells showed cytological features of repetitive DNA replication during the last cell cycle (Figure 2 ) while in control cultures maintained in the medium with tetracycline the number of such cells was less than 0.08% (Table 2) .
Next we analysed the eects of ras in p53-positive cells. For this purpose we used cell lines with dierent pattern of p53 response to ras activation. In REF52 and LIM1215 cells expression of ras oncogene leads to accumulation of p53 protein in the way similar to that described for primary embryonic cells (Serrano et al., 1997) , while in Rat1 and Rat2 there seem to be a defect in pathways responsible for ras-induced p53 stabilization (Ivanov et al., manuscript in preparation; also see Figure 3 ). Accordingly, the growth rate of ras-transformed REF52 and LIM1215 cells was somewhat decreased as compared with non-transformed counterparts (their Figure 1 Morphological transformation of MDAH041/tet-ras, Rat1/tet-ras and REF52/tet-ras cells caused by tetracycline withdrawal. Left column ± cultures permanently incubated in the medium with 1.0 mg/ml of tetracycline; right column ± parallel cultures incubated in tetracycline-free medium for 5 days doubling time was increased 1.2-and 1.7-fold, respectively) whilst in Rat1 and Rat2 cells ras expression caused some increase rather than a decrease in growth rate.
Induction of ras expression in Rat1 and Rat2 cell lines either by tetracycline withdrawal (Rat1/tet-ras cell line) or by addition of dexamethazone (Rat2/5 and Rat2-HT1 cell lines) was accompanied by 4 ± 5-fold increase in the number of chromosome breaks in dividing cells (Table 1) , as well as by signi®cant augmentation in the number of cells with chromosome endoreduplication (Table 2) . So, karyotypic eects of ras expression in p53-positive cell lines that do not show p53 accumulation in response of ras expression were similar to those observed in p53-negative MDAH041 cells. It should be mentioned that N-ras proto-oncogene in Rat2/5 subline was equally potent in induction of chromosome breaks and endoreduplication as activated H-ras leu12 oncogene in Rat2-HT1 subline (Tables 1 and 2) .
On the other hand, expression of activated ras showed considerably less prominent eects on karyotype stability in REF52 cell line (Tables 1  and 2 ), although it caused changes in cell morphology similar to those observed in Rat1 cells (Figure 1 ). In REF52 cells it did not change frequency of endoreduplication and polyploidy, and increased frequency of chromosome breaks less than twofold. Similar results were obtained with human Figure 2 Metaphase fragments of MDAH041/tet-ras and REF52/GSE-ras cells showing endoreduplication. Long arrows ± chromosome breaks, short arrows ± dicentrics resulted from breaks and recombinations of homologous re-replicated chromosomes (Tables 1 and 2 ). It is noteworthy that unlike Rat1 and Rat2 cells, the REF52 and LIM1215 cell lines show accumulation of p53 in response to ras expression (Figure 3 ). Probably p53 activation either interferes with ras-induced genetic changes or inhibits division of cells with such abnormalities.
In agreement with these suppositions we have found that REF52 cell sublines expressing dominant-negative p53s (either GSE22 or mutant p53-His175) show higher percentage of ras-induced chromosome breaks and endoreduplication/polyploidy as compared with control sublines bearing insert-free retroviral vector (Figure 4) . Similarly, transduction of mutant p53 into LIM1215 was accompanied by prominent (about 2 ± 3-fold) increase in the number of ras-induced chromosome abnormalities.
In¯uence of ras expression on G0/G1-to-S and G2-to-M transitions in mutagen-treated cells
To learn more on possible mechanisms underlying rasinduced chromosome instability we analysed the eects of ras expression on G1/S and G2/M cell cycle checkpoints that are activated in response to treatment with DNA-damaging agents. We used alkylating agent, ethyl metanesulphonate (EMS), whose application caused functional activation of p53 in both REF52 and Rat1 cell lines as was seen from increase in expression of the CAT reporter gene governed by p53-responsive promoter ( Figure 5 ).
For the analysis of G1-to-S transitions we studied the ability of mutagen-treated and control cultures, previously synchronized in G0/G1, to incorporate 5-bromodeoxyuridine (5-BrdU), i.e. to enter S phase (for details see Materials and methods). We have found that all tested cell lines can be eciently synchronized in G0/G1 by serum starvation. According to FACSanalysis (not shown) after 48 h in serum-free medium 90 ± 95% of cells showed 2n DNA content. Only 4 ± 7% of cells were able to incorporate 5-BrdU (Table 3) . After transfer to complete medium the majority of cells in all synchronized cultures started to enter the S phase. Fifteen hours after addition of serum they contained 65 ± 75% of 5-BrdU-positive cells (Table 3) . Treatment with 600 mg/ml of EMS 1.5 h after addition of serum signi®cantly decreased the number of cells entering S phase in p53-positive Rat1 and REF52 cell lines. In these cell lines expression of ras oncogene did not in¯uence 5-BrdU incorporation after treatment with mutagen. However in REF52 subline that contains dominant-negative p53 fragment (REF52/ GSE) and shows less prominent G1-arrest in response to EMS treatment, the expression of ras oncogene caused clear increase in the number of 5-BrdU-positive cells in mutagen-treated cultures. Similar eect of ras expression was observed in p53-negative MDAH041 cells (Table 3) .
Along with stimulation of G0/G1-to-S phase transition the expression of ras oncogene can inhibit EMS-induced G2 cell cycle arrest. Indeed, the tested ras-untransformed cell lines showed signi®cant decrease in the number of cells entering mitosis 2 ± 4 h after addition of DNA-damaging agent (Table 4) . Inhibition of G2-to-M transition was observed also in ras- Figure 4 In¯uence of dominant-negative p53 constructs on the frequency of ras-induced karyotypic changes in REF52 cells. Rastransformed cell sublines bearing exogenous p53 with mutation Arg-4His at codon 175 or dominant-negative p53 fragment (GSE) showed higher frequency of chromosome breaks and endoreduplication/polyploidy as compared with their counterparts containing the empty pPS/neo vector Figure 5 Activation of the cat gene reporter governed by p53-responsive promoter in Rat1-CAT and REF52-CAT cells treated with ethylmethan sulphonate (EMS, 600 mg/ml) for 12 h. CAT assay was performed as described in Materials and methods. Percent conversion of chloramphenicol to its acetylated product was estimated as the mean of three separate experiments; standard deviations are indicated p53-dependent effects of ras oncogene LS Agapova et al expressing REF52 cells. However, in REF52 cells bearing dominant-negative p53 and in some other ras-transformed cell cultures (p53-negative MDAH041 and p53-positive Rat1) treatment with EMS caused no signi®cant decrease in the number of cells entering mitosis (Table 4) . Thus expression of ras in cells showing p53 inactivation (MDAH041, REF52/GSE) or defects in signaling responsible for ras-induced p53-upregulation (Rat1) can abolish delay in G2-to-M transition following treatment with mutagen.
Discussion
Our results indicate that ras oncogene can induce karyotypic instability, but ecacy of its eect is dependent on the activity of p53-related signaling pathways. Indeed, in p53-negative MDAH041 cell line expression of exogenous ras signi®cantly increases frequency of spontaneous chromosome breaks as well as chromosome endoreduplication and polyploidy. Similar eects were observed in Rat1 and Rat2 cell lines that have lost the ability to accumulate p53 in response to ras hyperexpression. On the contrary, in REF52 and LIM1215 cell lines expression of ras caused accumulation of p53 and did not lead to signi®cant increase in the frequency of karyotypic changes in dividing cells. Since the overwhelming majority of cells in all tested cultures were able to incorporate 5-BrdU, one can conclude that lower incidence of chromosome abnormalities in REF52 and LIM1215 cells could not be explained by selective analysis of the cells that had lower ras and p53 expression and thus retained the ability to proliferate. Inactivation of the p53 function in REF52 and LIM1215 cells by dominant-negative mechanism increased the frequency of ras-induced chromosomal abnormalities in mitotic cells. These data are in agreement with the suggestion that expression of rasinduced chromosome instability is dependent on the p53 state. It was reasonable to suppose that karyotypic instability in ras-expressing cells is due to the ability of ras oncogene to aect the cell cycle checkpoints. In order to check this possibility we analysed the in¯uence of ras expression on G1-to-S and G2-to-M transitions in mutagen-treated cells. We found clear eects of ras on both G1-and G2-cell cycle checkpoints activated in response to treatment with EMS. These eects were dependent, however, on the activity of p53. In fact, in REF52 cells with functional p53 expression of ras oncogene aected neither G1-to-S nor G2-to-M transitions, while in REF52 subline expressing dominant-negative p53 as well as in p53-negative MDAH041 cell line ras caused a decrease in the number of cells arrested in G1 and G2 after mutagen treatment. Interestingly, the sequential inactivtion of p53 and enhancement of ras oncogene expression caused quantitative changes in control of G1-to-S transitions. One of possible explanations for this observations might be the involvement of both p53 and ras in regulation of common signaling pathway that is fully responsible for G1 exit. In seems probable that the common target for both p53 and ras could be the G1 cyclin/Cdk complexes. Indeed, p53 up-regulates p21
, an inhibitor of a set of Cdks and in particular of Cdk2 and Cdk4 (El-Deiry et al., 1993 Harper et al., 1993; Xiong et al., 1993; Dulic et al., 1994; Sherr and Roberts, 1995) , while activated ras is able to induce degradation of Cdk2 inhibitor, p27 kip1 (Fan and Bertino, 1997; Kawada et al., 1997) , to upregulate expresion of cyclic D1 (Filmus et al., 1994; Liu et al., 1995; Winston et al., 1996) and to control by these mechanisms the Rb-E2F signaling responsible for G1-to-S transition (Fan and Bertino, 1997; Pepper et al., 1997) . It can not be excluded that in damaged cells retaining some activities of Cdk2 and Cdk4 as a result of p53 dysfunction, the levels of cyclin D1 and/or Cdk2 activity may represent limiting factor(s) for G1 exit. If this is the case, the activated ras can allow to overcome . It is noteworthy that we observed substantial dierences in regulation of G1 and G2 checkpoints by p53 and ras. Indeed, both REF52 cells bearing dominant-negative p53 construct and p53-negative MDAH041 cells showed partial loss of the G1/S cell cycle checkpoint but retained the ability to respond to EMS treatment by G2 cell cycle arrest. This observations agrees with earlier ®nding that in human diploid ®broblasts expression of mutant p53 eectively abolishes the G1/S but not G2/M arrest following exposure to bleomycin (Wyllie et al., 1995) . In addition it was shown recently that expression of dominant-negative p53 constructs (p53-Ala143 or p53 miniprotein) is insucient to abrogate g-radiationinduced delay of G2-to-M transition in majority of human IMR-90 lung ®broblasts (Thompson et al., 1997) . Since in p53-defective cells ras almost completely abrogates the G2 delay it seems reasonable to suppose that the G2 checkpoint has complex, at least two-component control, and that p53 and ras regulate functions of dierent components of this checkpoint. Although the involvement of p53 in control of G2/M cell cycle checkpoint is well documented (Stewart et al., 1995; Agarwal et al., 1995; and others) , its mechanism remains to be established. Some data indicate the involvement of p21 waf1/cip1 -Cdc2 pathway in mediation of p53-induced G2 arrest (Chen et al., 1996; Medema et al., 1998) , however, the role in this phenomenon of other p53 targets such as gadd45 is not excluded. The rasregulated components of G2 cell cycle checkpoint are yet unknown and also require special investigation.
In agreement with certain relaxation of cell cycle checkpoints the ras-expressing cells were characterized by increased frequency of chromosome breaks in dividing cells. It should be noted, however, that the most prominent karyotypic eect of ras expression was the induction of endoreduplication. This event re¯ects uncoupling of the S phase and mitosis that leads to repetitive replication of nonsegregated chromosomes. Molecular basis for this phenomenon remains poorly understood. Earlier it was shown that the probability of endoreduplication can be increased by inactivation of p21 waf1/cip1 (Waldman et al., 1996) or overexpression of cyclin E, but not cyclin D1 (Mumberg et al., 1996) . Since in some systems activated ras up-regulate cyclin E (Fan and Bertino, 1997) it can not be excluded that ras-cyclin E signaling along with simulataneous inactivation of p53-p21 waf1/cip1 -Cdk pathway are responsible for induction of endoreduplication in our experiments. Interestingly, the ras-transformed Rat1 cells that retained p53-mediated G1 checkpoint, but unlike ras-transformed REF52 and LIM1215 cells showed no G2/M delay following treatment with EMS (this might be connected either with relatively lower p53 content in these cells due to a defect in signaling pathways responsible for rasinduced p53 accumulation or with some changes in p53 downstream targets responsible for control of G2-to-M transition) were highly permissive for induction by ras of chromosome instability. Probably dysfunction of the checkpoint(s) controlling G2-to-M transitions is sucient for an increase in the frequency of metaphases with both chromosome breaks and endoreduplication. 50 mM KCl, 0.5 mM MCl 2 , 0.1 mM EDTA, pH 6.8), containing 4% polyethylene glycol (M r 40 000) for 3 min and hydrolysed by 4M HCl at room temperature for 10 min. 5-BrdU incorporation was revealed by indirect immunostaining with BU-33 monoclonal mouse antibody speci®c to 5-BrdU (Sigma) and TRITC-conjugated antimouse IgG (Sigma). In each experiment the ecacy of cell synchronization was controlled by comparison of the percentages of cells incorporating 5-BrdU in cultures incubated in serum-free or in complete media.
For analysis of the G2-to-M transitions EMS (600 mg/ml) or equal volume of PBS were added 4 h before ®xation. The last 2 h cells were incubated in the presence of colcemid (Sigma, 0.1 mg/ml) allowing to arrest in mitosis the cells which exited G2. In each case more than 1000 cells were scored to determine the percentage of mitotic cells in mutagen-treated and -untreated cell cultures.
Western blot analysis of p53 expression 10 7 of cells were washed twice with ice-cold PBS and lysed in 0.5 ml of buer containing 20 mM HEPES pH 7.6, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 20% glycerol, 0.1% Triton X-100, 1 mM dithiotreitol and 10 mg/ml of aprotinin (Sigma). Nuclei obtained after low-speed centrifugation were shaken at 08C for 45 min in 30 ± 60 ml of the same buer supplemented with 500 mM NaCl. After centrifugation at 10 000 r.p.m. for 10 min nuclear extracts were separated on 10% SDS ± PAGE. Proteins were transferred onto nylon membranes, probed with panspeci®c Pab122 monoclonal antibodies and developed using ECL Western blotting kit (Amersham).
CAT assay was performed using Rat1-CAT and REF52-CAT cell sublines expressing the cat (chloramphenicol acetyltransferase) reporter gene under the control of p53-responsive waf1 gene promoter . EMS-treated and control cells were harvested by scarping in 25 mM Tris HCl and subjected to three cycles of freezing and thawing. Lysates were then incubated at 658C for 10 min to inactivate potential inhibitors of CAT, and samples containing equal amounts of protein were analysed for CAT activity using [ 14 C]chloraphenicol and thin layer chromatography as described elsewhere. The autoradiograms were scanned by ScanNex IIc (Extel Technology) using PictureMan Software. For quantitation of the amounts of acetylated [ 14 C]chloraphenicol the ImageQuant Software (version 3.3, Molecular Dynamics) was used.
